Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study-Reference-Cited by-同舟云学术

Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study

Published:2020-06-14 Issue:10 Volume:29 Page:1263-1272
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Althunian Turki A.¹^ORCID,Boer Anthonius¹²,Groenwold Rolf H. H.¹³,Rengerink Katrien O.³,Souverein Patrick C.¹,Klungel Olaf H.¹³

Affiliation:

1. Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht The Netherlands

2. Chairman of the Dutch Medicines Evaluation Board Dutch Medicines Evaluation Board Utrecht The Netherlands

3. Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht The Netherlands

Funder

The Saudi Food and Drug Authority

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5065

Reference39 articles.

1. Observational Research, Randomised Trials, and Two Views of Medical Science

2. Allocation concealment in randomised trials: defending against deciphering

3. Explanatory and pragmatic attitudes in therapeutical trials

4. Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Making causal inferences from transactional data: A narrative review of opportunities and challenges when implementing the target trial framework;Journal of International Medical Research;2024-03

2. Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials;JAMA Network Open;2023-09-27

3. Implementation of the trial emulation approach in medical research: a scoping review;BMC Medical Research Methodology;2023-08-16

4. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis;JAMA Neurology;2023-08-01